Effect of high-dose Statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure - Randomized, controlled, open-label, prospective pilot study

Circulation Journal

Volumn 78, Issue 10, 2014, Pages 2447-2454

  Oh, Jaewon ^a   Kang, Seok Min ^a   Hong, Namki ^a   Youn, Jong Chan ^a   Park, Sungha ^a   Lee, Sang Hak ^a   Choi, Donghoon ^a  

^a Yonsei University Health System   (South Korea)

Author keywords

Acute decompensated heart failure; Biomarkers; Statins

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; CYSTATIN C; BRAIN NATRIURETIC PEPTIDE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PYRROLE DERIVATIVE;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; KIDNEY INJURY; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ACUTE KIDNEY FAILURE; BLOOD; COMPLICATION; HEART FAILURE; HOSPITALIZATION; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PILOT STUDY; VERY ELDERLY;

ACUTE KIDNEY INJURY; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HEPTANOIC ACIDS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRROLES;

EID: 84908242091     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0670     Document Type: Article

References (39)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-e327, doi:10.1161/CIR.0b013e31829e8776.
2. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, et al. Acute decompensated heart failure: Update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-389.
3. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805.
4. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304.
5. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. JAMA 2013; 310: 2533-2543.
6. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-678.
7. Patti G, Chello M, Pasceri V, Colonna D, Nusca A, Miglionico M, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: Results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006; 48: 1560-1566.
8. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278.
9. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: The STATIN STEMI trial. JACC Cardiovasc Interv 2010; 3: 332-339.
10. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54: 558-565.
11. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: A collaborative patient-level metaanalysis of 13 randomized studies. Circulation 2011; 123: 1622-1632.
12. Benjo AM, El-Hayek GE, Messerli F, Dinicolantonio JJ, Hong MK, Aziz EF, et al. High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: A meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv 2013 December 21, doi:10.1002/ccd.25302.
13. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome). J Am Coll Cardiol 2014; 63: 71-79.
14. Subramanian S, Emami H, Vucic E, Singh P, Vijayakumar J, Fifer KM, et al. High-dose atorvastatin reduces periodontal inflammation: A novel pleiotropic effect of statins. J Am Coll Cardiol 2013; 62: 2382-2391.
15. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
16. Oh J, Kang SM, Hong N, Choi JW, Lee SH, Park S, et al. Relation between red cell distribution width with echocardiographic parameters in patients with acute heart failure. J Card Fail 2009; 15: 517-522.
17. Oh J, Kang SM, Won H, Hong N, Kim SY, Park S, et al. Prognostic value of change in red cell distribution width 1 month after discharge in acute decompensated heart failure patients. Circ J 2012; 76: 109-116.
18. Teng JF, Gomes T, Camacho X, Grundy S, Juurlink DN, Mamdani MM. Impact of the JUPITER trial on statin prescribing for primary prevention. Pharmacotherapy 2014; 34: 9-18.
19. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(Suppl): S1-S45.
20. Romayne Kurukulasuriya L, Athappan G, Saab G, Whaley Connell A, Sowers JR. HMG CoA reductase inhibitors and renoprotection: The weight of the evidence. Ther Adv Cardiovasc Dis 2007; 1: 49-59.
21. Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818-826.
22. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014; 63: 62-70.
23. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014; 35: 455-469.
24. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager P., Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006; 97: 1602-1606.
25. Sorof J, Berne C, Siewert-Delle A, Jorgensen L, Sager P. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract 2006; 72: 81-87.
26. Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: A post hoc analysis from the JUPITER study (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). Clin Ther 2011; 33: 717-725.
27. Wu Y, Wang Y, An C, Dong Z, Liu H, Zhang Y, et al. Effects of rosuvastatin and atorvastatin on renal function: Meta-analysis. Circ J 2012; 76: 1259-1266.
28. Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system. PLoS One 2011; 6: e28124, doi:10.1371/journal.pone.0028124.
29. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. Use of high potency statins and rates of admission for acute kidney injury: Multicenter, retrospective observational analysis of administrative databases. BMJ 2013; 346: f880.
30. Douglas K, O’Malley PG, Jackson JL. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124.
31. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: Prevalence and prognostic importance. Lancet 2009; 374: 543-550.
32. Masson S, Latini R, Milani V, Moretti L, Rossi MG, Carbonieri E, et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: Data from the GISSIHeart Failure trial. Circ Heart Fail 2010; 3: 65-72.
33. Koyama S, Sato Y, Tanada Y, Fujiwara H, Takatsu Y. Early evolution and correlates of urine albumin excretion in patients presenting with acutely decompensated heart failure. Circ Heart Fail 2013; 6: 227-232.
34. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: A report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009; 54: 1850-1859.
35. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A retrospective analysis. Circulation 2009; 120: 2188-2196.
36. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebocontrolled trial. Lancet 2013; 381: 29-39.
37. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: Correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206.
38. Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: Results from the CORONA trial. Circ Heart Fail 2014; 7: 96-103.
39. Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2014; 2: 65-72.